Harnessing IgM for solid tumor therapy: biology, engineering advances, and translational challenges

TL;DR

This paper explores how IgM antibodies could be used to treat solid tumors, highlighting their advantages and the challenges in developing them as therapies.

Contribution

The paper reviews recent engineering advances in IgM-based antibodies and outlines translational challenges for solid tumor therapy.

Findings

IgM antibodies show higher avidity and complement activation compared to IgG, making them effective in heterogeneous tumor environments.

Engineered IgM formats demonstrate antitumor potential in preclinical studies.

Key barriers include short serum half-life, poor tumor penetration, and production scalability.

Abstract

Immunoglobulin M (IgM) antibodies are gaining renewed attention as next-generation platforms for cancer immunotherapy. Compared with IgG, IgM exhibits distinct biological advantages, including higher avidity from multivalent binding, potent complement activation, and enhanced recognition of heterogeneous tumor antigens within immunosuppressive microenvironments. These attributes position IgM as a promising candidate for solid tumor therapy, despite the absence of currently approved IgM-based therapeutics. Recent advances in genetic engineering, antibody design, and protein manufacturing have enabled the generation of diverse IgM formats—ranging from monoclonal and bispecific constructs to engineered IgM derivatives—demonstrating substantial antitumor potential in preclinical and early translational studies. Nonetheless, clinical development faces persistent challenges, including short serum half-life, restricted tumor penetration, structural and biophysical complexity, and scalability of production. In this review, we discuss the structure and biology of IgM, highlight progress in developing novel IgM-based antibody formats for solid tumors, and critically examine the key translational barriers and future opportunities. Together, these insights underscore the therapeutic promise of IgM and chart a path toward its integration into the next generation of antibody-based cancer immunotherapies.

Figures